Psychotropic and neurotropic agents in dermatology: unapproved uses, dosages, or indications.
Koo
John Y
JY
Department of Dermatology, Psoriasis Treatment Center, Phototherapy Unit, University of California at San Francisco School of Medicine, California, San Francisco, USA.
Ng
Theresa C
TC
D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017277:Drug Approval; D004348:Drug Labeling; D004363:Drug Utilization; D005260:Female; D006801:Humans; D008297:Male; D009414:Nerve Growth Factors / Q000008:administration & dosage* / Q000009:adverse effects; D011379:Prognosis; D011602:Psychophysiologic Disorders / Q000175:diagnosis / Q000188:drug therapy; D011619:Psychotropic Drugs / Q000008:administration & dosage* / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D018967:Risperidone; D012680:Sensitivity and Specificity; D012871:Skin Diseases / Q000188:drug therapy* / Q000523:psychology*; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D003879:Dermatologic Agents; D009414:Nerve Growth Factors; D011619:Psychotropic Drugs; D018967:Risperidone